Format

Send to

Choose Destination
BMC Cancer. 2018 Dec 13;18(1):1247. doi: 10.1186/s12885-018-5156-1.

Management of uterine sarcomas and prognostic indicators: real world data from a single-institution.

Author information

1
Department of Clinical Therapeutics, Oncology Unit, Alexandra Hospital, Vasilisis Sofias, 80, Athens, Greece. tassoskyr@gmail.com.
2
Department of Clinical Therapeutics, Oncology Unit, Alexandra Hospital, Vasilisis Sofias, 80, Athens, Greece.
3
Obstetrics and Gynecology Department, Alexandra Hospital, Vasilisis Sofias, 80, Athens, Greece.
4
Pathology Department, Alexandra Hospital, Vasilisis Sofias, 80, Athens, Greece.

Abstract

BACKGROUND:

Uterine sarcomas consist a heterogeneous group of mesenchymal gynecological malignancies with unclear therapeutic recommendations and unspecific but poor prognosis, since they usually metastasize and tend to recur very often, even in early stages.

METHODS:

We retrospectively analyzed all female patients with uterine sarcomas treated in our institution over the last 17 years. Clinico-pathological data, treatments and outcomes were recorded. Kaplan-Meier curves were plotted and time-to-event analyses were estimated using Cox regression.

RESULTS:

Data were retrieved from 61 women with a median age of 53 (range: 27-78) years, at diagnosis. Fifty-one patients were diagnosed with leiomyosarcoma (LMS), 3 with high grade endometrial stromal sarcoma (ESS), 5 with undifferentiated uterine sarcoma (UUS), 1 with Ewing sarcoma (ES) and 1 with Rhabdomyosarcoma (RS). 24 cases had stage I, 7 stage II, 14 stage III and 16 stage IV disease. Median disease-free survival (DFS) in adjuvant approach was 18.83 months, and median overall survival (OS) 31.07 months. High mitotic count (> 15 mitoses) was significantly associated with worse OS (P < 0.001) and worse DFS (P = 0.028).

CONCLUSIONS:

Mitotic count appears to be independent prognostic factor while further insights are needed to improve adjuvant and palliative treatment of uterine sarcomas.

KEYWORDS:

Mitotic index; Prognostic factors; Uterine sarcomas

PMID:
30541504
PMCID:
PMC6292121
DOI:
10.1186/s12885-018-5156-1
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center